(NIH/National Institute of Mental Health) The FDA has approved brexanolone, an analog of the endogenous human hormone allopregnanolone and the first drug specifically designed to treat postpartum depression. FDA approval represents the final phase of a bench-to-bedside journey for this drug -- a journey that began in the NIMH Intramural Research Program (IRP). Want to learn more about this story? NIMH experts are available to provide information on postpartum depression and the importance of, and the science underlying, brexanolone.
from EurekAlert! - Social and Behavioral Science https://ift.tt/2Ycrshd
No comments:
Post a Comment